Objectives: A significant proportion of the older population may exhibit vitamin D insufficiency. We sought to establish the proportion of 25-hydroxyvitamin D (25OHD) insufficient individuals in an older female cohort presenting for acute medical admission and how they responded to supplementation. Design: A prospective cohort study. Setting: Hospital admissions followed up as a population-based study. Subjects: A total of 114 consecutive female acute medical admissions aged over 65 years from November 2003 to January 2004 were enrolled. All admissions with hypercalcaemia, metabolic bone disease (other than osteoporosis/osteomalacia) and creatinine 4150 mmol/l were excluded. Interventions: iPTH, calcium and 25OHD levels were measured in each patient. Of the total, 22 were already receiving calcium and vitamin D supplementation at enrolment. The remaining 92 were commenced on 800 IU of vitamin D and 1 g calcium, and levels were reassessed after supplementation for 3 months. Results: 25-Hydroxyvitamin D insufficiency, as defined by a 25OHD concentration of o50 nmol/l, was present in 86 (75.4%) patients at initial assessment (mean 35.8 nmol/l, s.d. 23.3). Secondary hyperparathyroidism was present in only 36.7% of those with 25OHD deficiency at baseline. Of the total, 51 (44.7%) patients presented for follow-up. 25-Hydroxyvitamin D concentration increased in this group from 42.1 nmol/l (s.d. 26.6) to 59.5 nmol/l (s.d. 27.4) after supplementation, Po0.001, but 18(35.3%) still remained deficient. There was no significant change in iPTH or calcium following supplementation. Assessment of compliance revealed 6 (11.7%) admitted to partial or non-compliance. Conclusions: Insufficiency of 25OHD was very common in this cohort. Despite calcium and vitamin D supplementation, 25OHD concentrations failed to reach normality in a significant proportion. Maintaining vitamin D and calcium intake at the level of current recommended doses may not be sufficient to ensure adequate 25OHD stores.
Introduction
There is a growing recognition that a significant proportion of the older population may exhibit vitamin D insufficiency.
Such insufficiency is common in populations at risk, such as nursing home residents and the homebound elderly (Lips et al., 1987 (Lips et al., , 1988 Theiler et al., 1999) , and it has also been described in the independent older population (Chapuy et al., 1996 (Chapuy et al., , 1997b Jacques et al., 1997) . Thomas et al. (1998) showed a high level of hypovitaminosis D in unselected medical inpatients (57%) using 37 nmol/l as a cut-off concentration. As categorized by Chapuy et al. (1997a) , vitamin D insufficiency needs to be distinguished from vitamin D deficiency, wherein the former has a biologic effect on calcium homeostasis and skeletal metabolism while the latter leads to osteomalacia.
25-Hydroxyvitamin D (25OHD) insufficiency may be caused by reduced cutaneous production of vitamin D, reduced intestinal absorption or very rarely impaired hepatic 25-hydroxylation or increased catabolism (liver induction). Low serum 25OHD concentrations lead to a small decrease of serum 1,25-dihydroxyvitamin D (1,25(OH) 2 D) and calcium absorption. The lower serum calcium concentration causes increased PTH secretion, stimulating the production of 1,25(OH) 2 D. By this mechanism, serum 1,25(OH) 2 D is kept at (nearly) normal concentrations at the expense of a raised PTH concentration, referred to as secondary hyperparathyroidism. This secondary hyperparathyroidism can result in increased bone turnover and bone loss mainly from cortical sites such as the femoral neck (Gloth, 1995; Schmidt-Gayk et al., 1997; Gloth, 1999) . Impaired vitamin D status has also been shown to affect muscle strength (Boland, 1986) , body sway and risk of falling (Stein et al., 1999) . It has been recognized for some time that at temperate latitudes serum 25OHD exhibits an annual cyclic variation, with a peak in late summer and a nadir in late winter. It has also been shown in older people in whom vitamin D concentrations are slightly low that supplementation with 800 IU of vitamin D and calcium substantially reduced the risk of osteoporotic fractures (Chapuy et al., 2002) .
The vitamin D status and the impact of supplementation on older community-dwelling females remain unclear. This study was performed to establish the proportion of 25OHD-insufficient female patients in an older cohort who presented for acute medical admission to an acute teaching hospital, how they responded to supplementation and whether such supplementation in this group would unmask asymptomatic hyperparathyroidism.
Materials and methods
A group of 117 consecutive female acute medical admissions aged over 65, admitted to University College Hospital, Galway, Ireland over a 3-month period from November 2003 to January 2004, was enrolled in the study. The city of Galway is at a latitude of 53.171 north. The study was approved by the Clinical Research Ethics Committee and all patients gave written, informed consent. Any patients with known metabolic bone disease (other than osteoporosis or osteomalacia) or documented hypercalcaemia were excluded. Those patients with overt renal impairment (creatinine 4150 mmol/l) were also excluded because this results in impaired hydroxylation of 25OHD to 1,25(OH) 2 D, the active form of vitamin D. A control group of 19 healthy volunteers was also recruited during the same period. These were all laboratory workers who were females and aged 24-60 years. An age-matched control group was not recruited as it was felt that it was unethical not to supplement a population who were likely to be 25OHD insufficient.
Two patients who were initially enrolled were excluded as they were under the age of 65 years at the time of initial recruitment. Similarly, one further patient was excluded as she was hypercalcaemic at baseline, leaving a total number of patients of 114.
Full clinical evaluation was undertaken at initial recruitment, followed by haematological and biochemical assessment. Blood was collected, transported to the laboratory on ice, centrifuged and serum aliquots either analysed that day for a profile, which included serum calcium and albumin, or stored frozen at À801C for later measurement of 25OHD and iPTH concentrations. Although 1,25(OH) 2 D is the most potent form of vitamin D, 25OHD is the main circulating metabolite of vitamin D and is considered the correct functional indicator of vitamin D stores in humans (Holick, 1990; Heaney, 1999) . Serum alkaline phosphatase and phosphorus concentrations were also measured. Of the 114 enrolled subjects, 22 were being prescribed calcium 1000 mg and vitamin D3 800 IU supplementation at the time of admission. Those who were not already on calcium and vitamin D supplementation at enrolment were commenced on vitamin D3 and calcium (1000 mg) supplementation daily for 3 months. Vitamin D3 was chosen as the appropriate form of supplementation as vitamin D2 has a markedly lower potency and shorter duration of action (Armas et al., 2004) . Serum calcium, albumin, 25OHD, iPTH, alkaline phosphatase and phosphorus concentrations were reassessed after 3 months in each patient from February to April 2004. Blood sampling was carried out in conjunction with repeat clinical examination. Compliance was established by direct questioning at 3-monthly review. Each patient who had returned for 3-monthly review was telephoned at a later date to further confirm compliance.
The laboratory participates in UK external Quality Assessment Schemes for all parameters measured. Serum 25OHD was measured using the manual Diasorin 25 hydroxyvitamin D 125 I RIA kit, which consists of a two-step procedure involving an extraction step followed by an equilibrium radio-immunoassay procedure. The Diasorin method for 25OHD has a negligible bias (Carter et al., 2004) . Serum iPTH was measured using the automated DPC Immulite 2000 method for quantitative assessment of intact PTH in serum or plasma using a solid-phase, two-site chemiluminescent enzyme-labelled immunometric assay. Serum calcium and albumin were measured on the Modular auto-analyser (Roche Diagnostics) in accordance with the manufacturer's instructions.
Alkaline phosphatase was measured on the Roche Diagnostics Modular P-800 Analyser using the IFCC standardized colorimetric assay based on the formation of p-nitrophenol at 371C. The laboratory reference range was 41-117 IU/l. Inorganic phosphorus was measured on the Roche Diagnostics Modular Analyser based on the formation of ammonium molybdate, with subsequent reduction to molybdenum blue. The laboratory reference range was 0.7-1.5 mmol/l. Calcium was corrected for serum albumin concentrations by using the formula: Calcium ðcorrected; mmol=lÞ ¼ Calcium ðmeasured; mmol=lÞ þ fð40 À albumin ðg=lÞÞÂ0:02g:
For the purpose of this study, those patients with a 25OHD level less than 50 nmol/l were considered to be vitamin D Vitamin D insufficiency in older population E DeLappe et al insufficient, as this is our hospital standard laboratory reference range. This value was chosen as it has been suggested that this concentration of 25OHD would restore serum iPTH values in the elderly to levels found in healthy young adults (Freaney et al., 1993) . A blunted iPTH response to 25OHD insufficiency was defined as an iPTH range o65 pg/ml, the quoted reference for our laboratory, and secondary hyperparathyroidism was defined as iPTH above this range.
Statistical analysis
Analysis was performed using SPSS for Windows 12 (SPSS Inc., Chicago, IL, USA). Baseline data are presented as mean7s.d. The Wilcoxon signed-rank test was used to determine if a statistically significant difference existed between the biochemical parameters before and after supplementation. Results with a value of Po0.05, two-tailed, were considered statistically significant. Spearman's rho was used to study the linear correlation between variables. Mann-Whitney U-test was used to compare biochemical parameters in those on supplementation with those not on supplementation, and to compare the iPTH concentrations in those who were 25OHD replete at baseline with those who were 25OHD insufficient.
Results

Baseline assessment
Initially 117 patients were recruited, and of these 114 were suitable for inclusion. A total of 22 patients were already on supplementation and were not newly commenced on calcium and vitamin D supplementation. Of the 114 patients, 92 were newly commenced on calcium and vitamin D supplementation. The mean age of the patients initially recruited was 79.7 years, with a range from 66 to 95 years. Mean 25OHD in the total group at baseline was 35.8 nmol/l (s.d. 23.3). 25-Hydroxyvitamin D insufficiency was identified in 86/114 of those initially recruited (75.4%), as defined by our cut-off point of 50 nmol/l. Of these, 29 patients (25.4%) had a 25OHD concentration of o20 nmol/l. Mean calcium at baseline was 2.36 mmol/l (s.d. 0.1) and mean iPTH at baseline was 56.7 pg/ml (s.d. 37.9). There was a significant negative correlation between intact PTH and 25OHD levels at baseline (P ¼ 0.01, Spearmans rho ¼ À0.384). Mean alkaline phosphatase in the total group at baseline was 103.5 IU/l (s.d. 69.1) and mean phosphorus was 1.1 mmol/l (s.d. 0.2). Mean 25OHD in the control group was 72.3 nmol/l.
Only 36.7% (31/86) of the subgroup with 25OHD insufficiency had secondary hyperparathyroidism, while the rest had an inappropriately low level of parathyroid hormone, indicating some degree of 'functional hypoparathyroidism' (Sahota et al., 2002) .
In those who had 25OHD insufficiency at baseline the mean iPTH concentration was 62.4 pg/ml (s.d. 40.9), while in those who were vitamin D replete the mean iPTH concentration was 39.2 pg/ml (s.d. 18.4). This was not statistically significant.
Supplementation versus no supplementation. Of those who were already on supplementation, 9/22 (40.9%) had 25OHD insufficiency with a mean 25OHD concentration of 62.2 nmol/l (s.d. 36.7), while of those who were not already on supplementation, 78/92 (84.8%) were 25OHD insufficient with a mean 25OHD of 30.5 nmol/l (s.d. 16.3). There was a statistically significant difference between 25OHD at baseline in these two groups (Po0.001).
Similarly, there was a significant difference between iPTH in those who were on supplementation prior to recruitment and those who were not (39.5 versus 60.8 pg/ml, P ¼ 0.014).
However, there was no significant difference in calcium concentrations between those already on supplementation and those who were not (2.37 versus 2.37 mmol/l, P ¼ 0.685)
3-Monthly assessment
Of the total group, only 51/114 (44.7%) patients returned for 3-monthly assessment. The baseline mean 25OHD concentration of these 51 patients was 42.09 nmol/l (s.d. 26.58) at enrolment. While there was a significant rise in 25OHD concentrations after 3 months supplementation of calcium and vitamin D, 25OHD levels remained insufficient in 18/51 (35.3%) patients. Mean 25OHD concentration in the follow-up group was 59.5 nmol/l (s.d. 27.4) and showed a statistically significant improvement (Po0.001). The mean increase in 25OHD was 0.87 nmol/mg/day. The mean PTH in the overall group at baseline and 3 months showed no statistically significant difference, nor did the mean calcium at baseline and 3 months, as shown in Tables 1  and 2 .
Of the 51 patients who returned for follow-up, 36 were 25OHD insufficient at baseline with a mean 25OHD of 28.9 nmol/l (s.d. 11.9). The mean 25OHD after treatment in these patients rose to 52.5 nmol/l (s.d. 26.4), which demonstrated a significant improvement (Po0.001). Despite this, 17 patients remained insufficient. In the other 15 patients who were not insufficient at baseline but who were supplemented, the mean 25OHD concentration rose from 73.9 nmol/l (s.d. 25.2) to 76.1 nmol/l (s.d. 22.5), which was not a statistically significant improvement.
There was no significant change in iPTH level following treatment in those who were 25OHD insufficient at the outset. Similarly, there was no significant change in calcium following treatment in this group either.
Six patients (11.7%) admitted to non-compliance at follow-up assessment and this figure may indeed have been higher, as we were relying on direct questioning to establish compliance.
No new cases of occult hyperparathyroidism following vitamin D and calcium supplementation were unmasked in this study, that is, supplementation did not result in an Vitamin D insufficiency in older population E DeLappe et al increase in calcium concentrations with an associated elevation of iPTH, which would be consistent with an unmasking of asymptomatic hyperparathyroidism.
Discussion
This study shows that there is a high prevalence of 25OHD insufficiency in community-dwelling older women, and, despite 3 months supplementation with calcium and a dosage of vitamin D exceeding the current recommended US adequate intake guidelines (Food and Nutrition Board Institute of Medicine, 1997), a high proportion remain insufficient. 25-Hydroxyvitamin D insufficiency has been commonly described in the institutionalized older population of the northern hemisphere, but it has recently been proposed that insufficiency may indeed be more common in the general population than previously thought (Chapuy et al., 1996 (Chapuy et al., , 1997b Jacques et al., 1997; Bettica et al., 1999; Aguado et al., 2000; Inderjeeth et al., 2000; Oliveri et al., 2004) . Combination calcium and vitamin D are commonly given for the treatment of osteoporosis. The largest study of the treatment with combination calcium (1.2 g) and vitamin D (800 IU) demonstrated an overall reduction in hip fractures of 43%, and nonvertebral fractures of 32% (Chapuy et al., 1992) . This clinical outcome was attributed to correction of secondary hyperparathyroidism and reduction in bone remodelling. However, recent studies have suggested that routine oral supplementation with calcium and vitamin D, either alone or in combination, may not be effective in the prevention of fractures in older people (Grant et al., 2005; Porthouse et al., 2005) .
We propose that there are a number of possible reasons that such a significant proportion of patients remained 25OHD insufficient at 3 months. It has previously been proposed that the dosage of 800 IU of supplemental vitamin D may be insufficient to result in normalization of 25OHD concentrations in those whose levels are insufficient. Heaney et al. (2003) , found a relatively small response to supplementation in the dosage range of oral vitamin D that is currently recommended (Food and Nutrition Board Institute of Medicine, 1997) . They calculated that a dose of 400 IU/day would elevate serum 25(OH)D 3 by only 7.0 nmol/l. Several groups have reached the same conclusion, namely that, without appreciable cutaneous synthesis, current cholecalciferol input recommendations are inadequate (Glerup et al., 2000; Vieth et al., 2001 ). There have been no studies showing toxic effects of higher doses of vitamin D, and Vieth et al. (2001) proposed that the evidence available today indicates that a value of 2000 IU/day for the tolerable upper input level is too low. The data presented by Heaney et al. (2003) actually support an average daily need of perhaps twice that amount. For osteoporosis prevention, a recent consensus is that adult consumption of vitamin D should be about 25 mcg (1000 IU)/day (Dawson-Hughes et al., 2004) . Indeed, it is possible that at recruitment, having given informed consent, patients would have been more aware of the need for dietary sources of vitamin D and that they may have made dietary changes that would account for some of the differences on follow-up. This would of course make the dose of 800 IU daily even less useful.
The period of supplementation may also have been inadequate. In a study comparing the effects on biochemical Vitamin D insufficiency in older population E DeLappe et al responses of vitamin D supplementation of an adequate intake level with 4000 IU/day, the greatest biochemical responses to vitamin D occurred after 6 months of supplementation (Vieth et al., 2004) . However, our period of supplementation was only half of that. Deposition of vitamin D metabolites in adipose tissue (storage) may have been a factor in the lack of increase in plasma levels after a relatively short treatment period. Of the 51 patients who returned for follow-up assessment, six admitted to non-compliance (11.7%). This figure was established by direct questioning on two separate occasions and also by discussing with the carer when available. This may of course have been an underestimation of the level of non-compliance. It is likely that non-compliance would be much more prevalent among those who failed to return for assessment. Unfortunately, in our study the administration of supplements was unsupervised and therefore our compliance rates are entirely based on direct questioning, which is less reliable (Loh et al., 2004) . If the non-compliance rates were indeed higher, it would certainly help explain the poor response of the group with 25OHD insufficiency to treatment. Ideally, we would have liked to directly administer the medication under supervision to each patient daily; however, as this group was community dwelling and the treatment period was for 3 months, this would not have been feasible. In any case, this reflects routine clinical practice. Vitamin D injection has previously been shown to be a cost-effective method of fracture prevention that may help overcome the significant problem of non-compliance (Torgerson et al., 1996) . However, a recent British study has shown that vitamin D injection, as opposed to oral administration, is without any effect on fracture risk (Smith et al., 2004) .
This study examined patients in wintertime when the effect of solar UVB is negligible at the latitudes of Ireland. UVB is the major source of vitamin D supplementation even in the elderly population and provides up to 80% of vitamin D. The low 25OHD concentrations at baseline could have been affected by the season and low 25OHD stores, but should not have affected the actual response to supplementation.
It is apparent from this study that just over one-third of the patients with 25OHD insufficiency did not have an adequate parathyroid hormone response at baseline. Previous studies have suggested that this may be a common occurrence (Bettica et al., 1999; Aguado et al., 2000) . The explanation for the impaired PTH response is not readily apparent. This blunted PTH response may protect against bone loss through decreased bone turnover, but is often associated with a disruption in calcium homeostasis as compared to patients with 25OHD insufficiency and secondary hyperparathyroidism (Sahota et al., 2004) . Dysfunction of the parathyroid glands may be a possible explanation, including abnormal parathyroid calcium-sensing receptors or abnormal 1,25(OH) 2 D receptors, although these were not assessed in this study.
Previously, calcium and vitamin D repletion had been shown to occasionally result in the unmasking of occult primary hyperparathyroidism (Taylor and Wise, 1997; Hannan et al., 2004) . However, our study did not demonstrate any such cases, although six patients who reached the vitamin D-repleted range showed a concomitant increase in iPTH above the normal range, but without a significant increase in calcium. One could argue that this inability to demonstrate unmasking of primary hyperparathyroidism with supplementation may have been due to an inadequate supplementation dose, non-compliance or an insufficient period of treatment. Though new-onset hypercalcaemia did not develop in any of the patients following 3 months of supplementation, the elevated PTH levels concomitant with the repletion of vitamin D stores in some of the patients need further investigation over a longer period of time to determine if the hyperparathyroidism persists.
Unfortunately, our follow-up rate was lower than that expected. This may have been due to the wide catchment area of the hospital and difficulties regarding transport to and from the hospital for the purpose of assessment. Another possible problem was that patients, having given informed consent, may have been more aware of the need for milk or other dietary sources of vitamin D, and they may have made dietary changes that would account for some of the differences on follow-up. Of course this would make the dose of 800 IU/day even less useful. Also, ideally, an age-matched control group should have been recruited to allow for comparison between groups with and without supplementation. However, due to the likelihood of high levels of 25OHD deficiency in this group, we felt that it was unethical not to supplement a deficient patient group.
From our study, we conclude that 25OHD insufficiency is more common than previously thought and is not restricted to high-risk groups. Despite supplementation of these patients with 1 g calcium and 800 IU vitamin D3, though there was a significant improvement in mean 25OHD levels, a large proportion remained insufficient. Maintaining vitamin D and calcium intake at the level of the current recommended daily amount may not be sufficient to ensure adequate vitamin D stores. The probability that 800 IU daily is not an adequate dose has important implications for clinical practice and the planning of future research studies. Compliance with calcium and vitamin D supplementation may also be an issue and therefore regular vitamin D injections (Torgerson et al., 1996) may be more practical in treating this population and needs to be investigated further. Owing to the potential negative effects of vitamin D insufficiency on the skeleton and other organ systems, widespread screening for vitamin D insufficiency and vitamin D supplementation at a higher dose should be considered. We suggest that 25OHD levels should be monitored before and after supplementation in all patients with 25OHD insufficiency to establish the response to treatment. If they remained 25OHD insufficient following Vitamin D insufficiency in older population
